Fig. 2: Mutational profile in CRc status and its effect on survival.

Kaplan–Meier curves showing OS (A) or RFS (B) stratified by hematological response to VEN + AZA treatment. P values are calculated by log-rank test. C Box plots showing the number of genetic alterations per case (left: SNV, middle: CNA, right: SV) for the 89 cases that achieved CRc and had both Pre-treatment and Best-response samples analyzed. P values are calculated with paired-t test. D Bar charts showing the ratio of genetic alterations that were shared between Pre-treatment and Best-response samples. E Stacked bar charts showing the frequency of the cases having non-DTA mutations (red), DTA-mutations alone (purple), or no mutations (blue). The x-axis shows the hematological responses. The 121 patients who had any mutations in either Pre-treatment or Best-response were included in the analysis. P values were calculated using Fisher’s exact test to compare the ratio of cases with non-DTA mutations between response categories. F Stacked bar charts showing the difference of residual mutation status in CRc status for 80 cases who received VEN + AZA and 80 cases who received intensive chemotherapy. P values were calculated using Fisher’s exact test to compare the ratio of cases with non-DTA-mutations between treatment groups. G Kaplan–Meier curves showing RFS stratified by the residual mutations (red: residual non-DTA-mutations, blue: no residual mutations or DTA-mutations alone) in CRc status. P-values are calculated by log-rank test. H Cumulative incidence curves showing relapse (straight lines) or non-relapse mortality (dotted lines) for the same cohort as (G). OS overall survival, RFS relapse-free survival, SNV single nucleotide variants, CNA copy number alterations, SV structural variants, CRc composite complete remission, DTA, DNMT3A, TET2, and ASXL1.